Five monoclonal antibody “cocktails,” including one developed at Vanderbilt University Medical Center (VUMC), are protective in animal studies against several variant strains of COVID-19, according to a report this week in the journal Nature.
Multisystem inflammatory syndrome (MIS) is the inflammation of various tissues and has been cited as a complication of SARS-CoV-2 infection. Originally identified in children, a form of MIS has since been described in adults (MIS-A).
Smokers who believed they were at increased risk of getting COVID-19 during the pandemic, or having a more severe case, were more likely to quit while those who perceived more stress increased smoking, according to new research published in the Journal of General Internal Medicine. The study, conducted by investigators at Vanderbilt University Medical Center, Massachusetts … Continued
The Vanderbilt Department of Hearing and Speech Sciences has conducted research to better understand how individuals with traumatic brain injury (TBI) have adapted to the COVID-19 pandemic. Researchers think the findings may apply to many disability populations in future crises.
Heparin and platelets are discouraged as treatment for patients who develop blood clots in the brain and low platelet counts 6-15 days after receiving Johnson & Johnson‘s Janssen COVID-19 vaccine, following a clinical investigation review of 12 U.S. cases conducted by the CDC and institutions including Vanderbilt University Medical Center.
The Vanderbilt Institute for Clinical and Translational Research (VICTR) has been awarded a major federal grant to lead a national trial of treatments targeting the Renin Angiotensin Aldosterone System (RAAS) in patients hospitalized with COVID-19.
Under the SARS CoV-2 Return to School Saliva Opt-in Screening Study, which began last November at University School of Nashville, a research team from Vanderbilt University Medical Center is testing a solution for efficient asymptomatic disease surveillance and control.
Vanderbilt University Medical Center (VUMC) has been named Data Coordinating Center (DCC) for a nationwide platform of studies aimed at “repurposing” existing drugs to treat mild to moderate symptoms of COVID-19. The Duke Clinical Research Institute (DCRI) is the Clinical Coordinating Center for the ACTIV-6 platform announced April 19 by the National Institutes of Health (NIH). … Continued
James Crowe, MD, and members of his lab at Vanderbilt University Medical Center who have pioneered rapid development of monoclonal antibody treatments for life-threatening viral diseases including COVID-19, were featured April 11 on a CBS News 60 Minutes segment titled “The Last Pandemic.”
The U.S. government has reserved up to 700,000 doses of a monoclonal antibody cocktail against the COVID-19 virus discovered at Vanderbilt University Medical Center and developed by AstraZeneca, officials have announced.